Current Report Filing (8-k)
February 21 2023 - 1:59PM
Edgar (US Regulatory)
0001419051
false
0001419051
2023-02-21
2023-02-21
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date
of Report (Date of earliest event reported): February 21, 2023
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC. |
(Exact
Name of Registrant as Specified in its Charter) |
Nevada |
|
000-54554 |
|
45-1226465 |
(State
or other jurisdiction of
incorporation
or organization) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
Number) |
701
Wild Rose Lane |
Elk
City, Idaho 83525 |
(Address
of Principal Executive Offices and Zip Code) |
|
(760)
295-7208 |
(Issuer’s
telephone number) |
|
|
(Former
Name or Former Address, if Changed Since Last Report) |
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item
1.01 Entry into a Material Definitive Agreement
On
February 17, 2023, Therapeutic Solutions International, Inc. and Veltmeyer Institute for Advanced Biologics, LLC, entered into an exclusive
patent license agreement for Right to Try, emergency Investigational New Drug (“IND”), and/or Expanded Access use within
the field of brain and lung for those conditions that are applicable included here in exhibit 10.1. In exchange TSOI has received 30%
of Veltmeyer Institute Management Company, LLC.
Item
8.01 Other Events.
The
information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference including reference to exhibits.
Item
9.01 Financial Statements and Exhibits.
Exhibit
Index
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Date:
February 21, 2023 |
|
|
|
|
THERAPEUTIC
SOLUTIONS INTERNATIONAL, INC. |
|
|
|
|
By:
|
/s/
Timothy Dixon |
|
|
Timothy
Dixon |
|
|
Chief
Executive Officer |
|
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Therapeutic Solutions (PK) (USOTC:TSOI)
Historical Stock Chart
From Apr 2023 to Apr 2024